Ritlecitinib Clinical Trials (2026): 25 Studies for Alopecia Areata & Healthy Volunteers
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
25 Ritlecitinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 13 indications (including Alopecia Areata & Healthy Volunteers) and 5,213 total planned enrollment. 6 Phase 3 Ritlecitinib trials and 7 Phase 2 are listed. 5 Ritlecitinib clinical trials are actively recruiting at 48 U.S. sites across 19 states. Most recent activity: NCT07029828 (Jun 2030).
Where to Participate: All Ritlecitinib Trial Sites in the U.S. (48 sites across 19 states)
Every actively recruiting Ritlecitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | The Kirklin Clinic of UAB Hospital (Radiology) | Birmingham35233 | NCT06873945 | Map |
| AL | University of Alabama at Birmingham | Birmingham35233 | NCT06873945 | Map |
| AL | University of Alabama at Birmingham Faculty Office Towers (Regulatory) | Birmingham35233 | NCT06873945 | Map |
| AR | Acuro Research, Inc. | Little Rock72205 | NCT07219615 | Map |
| CA | Kern Research. Inc. | Bakersfield93301 | NCT07219615 | Map |
| CA | Doc1 Healthcare Systems | Brea92821 | NCT06873945 | Map |
| CA | California Dermatology & Clinical Research Institute | Encinitas92024 | NCT07029828 | Map |
| CA | First OC Dermatology Research Inc | Fountain Valley92708 | NCT07219615 | Map |
| CA | Gavin Herbert Eye Institute | Irvine92697 | NCT06873945 | Map |
| CA | University of California - Irvine | Irvine92617 | NCT06873945 | Map |
| CA | Antelope Valley Clinical Trials | Lancaster93534 | NCT07219615 | Map |
| CA | Skin & Beauty Center - Pasadena | Pasadena91105 | NCT07219615 | Map |
| CO | Asthma and Allergy Associates, PC | Colorado Springs80907 | NCT07219615 | Map |
| CT | Brett King MD, LLC | Fairfield06824 | NCT06873945 | Map |
| FL | Pediatric Skin Research | Miami33156 | NCT06873945 | Map |
| FL | Pediatric Skin Research | Miami33156 | NCT07029828 | Map |
| FL | Skin Research of South Florida | Miami33173 | NCT06873945 | Map |
| IL | Asthma and Allergy Center of Chicago | River Forest60305 | NCT07219615 | Map |
| IN | Dawes Fretzin Clinical Research Group, LLC | Indianapolis46250 | NCT06873945 | Map |
| IN | Dawes Fretzin Clinical Research Group, LLC | Indianapolis46250 | NCT07029828 | Map |
| IA | University of Iowa | Iowa City52242 | NCT06873945 | Map |
| MD | Johns Hopkins University | Baltimore21218 | NCT06873945 | Map |
| MD | Dermatology and Skin Cancer Specialists, LLC | Rockville20850 | NCT06873945 | Map |
| MD | Chesapeake Clinical Research | White Marsh21162 | NCT07219615 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT07219615 | Map |
| MI | Revival Research Institute, LLC | Troy48084 | NCT07219615 | Map |
| MN | University of Minnesota Clinics and Surgery Center Department of Audiology | Minneapolis55455 | NCT06873945 | Map |
| MN | University of Minnesota Clinics and Surgery Center Department of Radiology | Minneapolis55454 | NCT06873945 | Map |
| MN | University of Minnesota Clinics and Surgery Center Department of Radiology | Minneapolis55455 | NCT06873945 | Map |
| MN | University of Minnesota Health Clinical Research Unit (M Health CRU) | Minneapolis55455 | NCT06873945 | Map |
| NE | Ear, Nose & Throat Consultants, LLC | Omaha68144 | NCT07029828 | Map |
| NE | Skin Specialists, PC dba Schlessinger MD | Omaha68144 | NCT07029828 | Map |
| NE | Complete Behavior Health (Dr. Brittany Marshall, Licensed Psychologist) | Papillion68046 | NCT07029828 | Map |
| NM | Regents of the University of New Mexico | Albuquerque87131 | NCT07029828 | Map |
| NM | University of New Mexico Health Sciences Center | Albuquerque87102 | NCT07029828 | Map |
| NM | University of New Mexico-IDS Pharmacy | Albuquerque87106 | NCT07029828 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT06373458 | Map |
| OH | Bexley Dermatology Research | Bexley43209 | NCT06873945 | Map |
| OK | Allergy, Asthma, & Clinical Research Center | Oklahoma City73120 | NCT07219615 | Map |
| OK | Vital Prospects Clinical Research Institute, PC | Tulsa74136 | NCT06873945 | Map |
| OR | Northwest Dermatology Institute | Portland97210 | NCT07029828 | Map |
| TX | Orion Clinical Research | Austin78759 | NCT07219615 | Map |
| TX | 3A Research | El Paso79902 | NCT07029828 | Map |
| TX | Center for Clinical Studies | Houston77004 | NCT06873945 | Map |
| TX | RFSA Dermatology - San Antonio - West Avenue | San Antonio78213 | NCT07219615 | Map |
| TX | Texas Dermatology and Laser Specialists | San Antonio78218 | NCT07029828 | Map |
| TX | Complete Dermatology | Sugar Land77479 | NCT07219615 | Map |
| TX | Center for Clinical Studies - Clear Lake | Webster77598 | NCT06873945 | Map |
Ritlecitinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | available | Total |
|---|---|---|---|---|---|---|---|
| P1 | 7 | 7 | |||||
| P2 | 2 | 2 | 1 | 1 | 1 | 7 | |
| P3 | 2 | 3 | 1 | 6 | |||
| N/A | 1 | 1 | 2 | 1 | 5 |
Recruiting Ritlecitinib clinical trials (5)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07029828 | B7981028A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. | P3 | Severe Alopecia Areata | 140 | Sep 2025 |
| NCT06873945 | ALLEGRO-100A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata | P3 | Alopecia Areata | 674 | Apr 2025 |
| NCT06373458 | Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy | P2 | Keloid | 30 | Aug 2024 |
| NCT07219615 | A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | P2 | Chronic Spontaneous Urticaria | 200 | Oct 2025 |
| NCT06573593 | Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study | — | Alopecia Areata | 150 | Jul 2024 |
Ritlecitinib clinical trials by indication
Alopecia Areata (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06531109 | PRESTO | N/A | active not recruiting | Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib |
| NCT06873945 | ALLEGRO-100 | P3 | recruiting | A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata |
| NCT06573593 | — | N/A | recruiting | Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study |
| NCT07226531 | — | N/A | completed | Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US |
| NCT05650333 | AA | P1 | completed | A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age |
| NCT05522556 | PF-06651600 | N/A | available | Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600) |
Healthy Volunteers (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06369454 | — | P1 | completed | A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food |
| NCT06172348 | — | P1 | completed | A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults |
| NCT05852340 | — | P1 | completed | A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants |
| NCT05097716 | PK | P1 | completed | Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide |
Severe Alopecia Areata (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07029828 | B7981028 | P3 | recruiting | A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. |
| NCT07029711 | B7981027 | P3 | active not recruiting | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata |
| NCT07200128 | — | N/A | completed | A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings |
Chronic Spontaneous Urticaria (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07219615 | — | P2 | recruiting | A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. |
| NCT06795373 | PF-06651600 | P2 | withdrawn | Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria |
Stable Nonsegmental Vitiligo (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06072183 | Tranquillo 2 | P3 | active not recruiting | A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 |
| NCT05583526 | Tranquillo | P3 | completed | A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo |
Hidradenitis Suppurativa (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07228390 | — | P2 | active not recruiting | A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. |
Keloid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06373458 | — | P2 | recruiting | Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy |
Vitiligo (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06163326 | Tranquillo LTE | P3 | active not recruiting | A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo |
Diabetes Mellitus, Type 1 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05743244 | JAK | P2 | active not recruiting | Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
CTCL (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05879458 | — | P2 | terminated | Ritlecitinib in CTCL |
Celiac Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05636293 | — | P2 | completed | Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05128058 | — | P1 | completed | A Target Occupancy Study With Ritlecitinib. |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05040295 | — | P1 | completed | A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults |
Ritlecitinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| B7981028 | NCT07029828 | P3 | recruiting | Severe Alopecia Areata | 140 | — |
| ALLEGRO-100 | NCT06873945 | P3 | recruiting | Alopecia Areata | 674 | PMID 41083802 |
| Tranquillo 2 | NCT06072183 | P3 | active not recruiting | Stable Nonsegmental Vitiligo | 1,571 | — |
| Tranquillo LTE | NCT06163326 | P3 | active not recruiting | Vitiligo | 394 | — |
| B7981027 | NCT07029711 | P3 | active not recruiting | Severe Alopecia Areata | 208 | — |
| Tranquillo | NCT05583526 | P3 | completed | Stable Nonsegmental Vitiligo | 607 | — |
| JAK | NCT05743244 | P2 | active not recruiting | Diabetes Mellitus, Type 1 | 78 | — |
| PF-06651600 | NCT06795373 | P2 | withdrawn | Chronic Spontaneous Urticaria | 0 | — |
Terminated and withdrawn Ritlecitinib trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06795373withdrawnRitlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
- NCT05879458terminatedRitlecitinib in CTCL
All Ritlecitinib trials (25)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07029828 | B7981028 | A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. | P3 | recruiting | 140 | Pfizer | Sep 2025 |
| NCT06531109 | PRESTO | Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib | — | active not recruiting | 450 | Pfizer | Aug 2024 |
| NCT06873945 | ALLEGRO-100 | A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata | P3 | recruiting | 674 | Pfizer | Apr 2025 |
| NCT06373458 | Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy | P2 | recruiting | 30 | Icahn School of Medicine at Mount Sinai | Aug 2024 | |
| NCT05743244 | JAK | Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) | P2 | active not recruiting | 78 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Oct 2023 |
| NCT06072183 | Tranquillo 2 | A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 | P3 | active not recruiting | 1,571 | Pfizer | Nov 2023 |
| NCT07219615 | A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | P2 | recruiting | 200 | Pfizer | Oct 2025 | |
| NCT06163326 | Tranquillo LTE | A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo | P3 | active not recruiting | 394 | Pfizer | Jan 2024 |
| NCT07029711 | B7981027 | A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | P3 | active not recruiting | 208 | Pfizer | Jul 2025 |
| NCT07228390 | A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. | P2 | active not recruiting | 128 | Pfizer | Nov 2025 | |
| NCT06573593 | Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study | — | recruiting | 150 | Second Affiliated Hospital, Zhejiang University, School of Medicine | Jul 2024 | |
| NCT05636293 | Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission | P2 | completed | 62 | Massachusetts General Hospital | Mar 2023 | |
| NCT06795373 | PF-06651600 | Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria | P2 | withdrawn | 0 | Ahuva D Cices | Dec 2025 |
| NCT07226531 | Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US | — | completed | 300 | Pfizer | Dec 2025 | |
| NCT05583526 | Tranquillo | A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo | P3 | completed | 607 | Pfizer | Dec 2022 |
| NCT05879458 | Ritlecitinib in CTCL | P2 | terminated | 7 | Icahn School of Medicine at Mount Sinai | May 2023 | |
| NCT07200128 | A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings | — | completed | 123 | Pfizer | Feb 2025 | |
| NCT06369454 | A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food | P1 | completed | 12 | Pfizer | May 2024 | |
| NCT06172348 | A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults | P1 | completed | 12 | Pfizer | Feb 2024 | |
| NCT05650333 | AA | A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age | P1 | completed | 15 | Pfizer | Mar 2023 |
| NCT05852340 | A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants | P1 | completed | 12 | Pfizer | May 2023 | |
| NCT05522556 | PF-06651600 | Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600) | — | available | 0 | Pfizer | — |
| NCT05128058 | A Target Occupancy Study With Ritlecitinib. | P1 | completed | 16 | Pfizer | Oct 2021 | |
| NCT05097716 | PK | Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide | P1 | completed | 12 | Pfizer | Nov 2021 |
| NCT05040295 | A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults | P1 | completed | 12 | Pfizer | Sep 2021 |
Ritlecitinib clinical trials: frequently asked questions
- How many Ritlecitinib clinical trials are there?
- 25 Ritlecitinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 11 are marked completed.
- Are Ritlecitinib clinical trials recruiting in 2026?
- Yes — 5 Ritlecitinib trials are actively recruiting in 2026, with 48 U.S. sites across 19 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Ritlecitinib being studied for?
- Ritlecitinib is being studied for Alopecia Areata, Healthy Volunteers, Severe Alopecia Areata, Active Nonsegmental Vitiligo, Chronic Spontaneous Urticaria and 15 more. The trials are grouped by indication on this page.
- What phase is Ritlecitinib in?
- Ritlecitinib clinical trials span 6 Phase 3, 7 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Ritlecitinib clinical trials?
- The lead sponsor across the most Ritlecitinib trials is Pfizer, with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ritlecitinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: